MGTX
MeiraGTx Holdings PLC
$
8.330
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.625
Open
8.440
VWAP
8.45
Vol
420.40K
Mkt Cap
669.44M
Low
8.0387
Amount
3.55M
EV/EBITDA(TTM)
--
Total Shares
64.31M
EV
677.22M
EV/OCF(TTM)
--
P/S(TTM)
17.78
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
6.85M
-37.22%
--
--
21.44M
+0.23%
--
--
2.63M
+36.4%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for MeiraGTx Holdings plc (MGTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 65.28%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+65.28%
In Past 3 Month
3 Analyst Rating
208.16% Upside
Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is 25.67 USD with a low forecast of 13.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
208.16% Upside
Current: 8.330
Low
13.00
Averages
25.67
High
50.00
208.16% Upside
Current: 8.330
Low
13.00
Averages
25.67
High
50.00
Lucid Capital
NULL -> Buy
initiated
$50
2025-06-09
Reason
Lucid Capital
Price Target
$50
2025-06-09
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of MeiraGTx with a Buy rating and $50 price target. MeiraGTx is developing next-generation, genetic medicines to potentially unlock cures in chronic diseases, the analyst tells investors in a research note. The firm says the company is "providing a toolbox to pharma."
RBC Capital
Luca Issi
Buy
Maintains
$11 → $13
2025-03-17
Reason
RBC Capital
Luca Issi
Price Target
$11 → $13
2025-03-17
Maintains
Buy
Reason
RBC Capital raised the firm's price target on MeiraGTx to $13 from $11 and keeps an Outperform rating on the shares after its Q4 results. The company is very pleased with the terms of the deal announced with private AI company Hologen and notes that the process was competitive, the analyst tells investors in a research note. MeiraGTx is also planning to submit an MAA with UK regulators based on its LCA4 results with no need for additional studies, and is in discussions with FDA on a path forward, the firm adds.
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$36
2025-02-24
Reason
Chardan Capital
Daniil Gataulin
Price Target
$36
2025-02-24
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$36
2024-11-18
Reason
Chardan Capital
Daniil Gataulin
Price Target
$36
2024-11-18
Maintains
Strong Buy
Reason
RBC Capital
Luca Issi
Buy
Maintains
$9 → $11
2024-11-14
Reason
RBC Capital
Luca Issi
Price Target
$9 → $11
2024-11-14
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for MeiraGTx Holdings PLC (MGTX.O) is -4.53, compared to its 5-year average forward P/E of -11.58. For a more detailed relative valuation and DCF analysis to assess MeiraGTx Holdings PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.58
Current PE
-4.53
Overvalued PE
21.06
Undervalued PE
-44.22
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.37
Current EV/EBITDA
6.38
Overvalued EV/EBITDA
7.25
Undervalued EV/EBITDA
-13.99
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
32.96
Current PS
16.85
Overvalued PS
64.92
Undervalued PS
1.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+176.33%
1.93M
Total Revenue
FY2025Q1
YoY :
-11.07%
-41.60M
Operating Profit
FY2025Q1
YoY :
+95.58%
-39.98M
Net Income after Tax
FY2025Q1
YoY :
+59.38%
-0.51
EPS - Diluted
FY2025Q1
YoY :
+0.31%
-38.54M
Free Cash Flow
FY2025Q1
YoY :
-71.55%
28.45
Gross Profit Margin - %
FY2025Q1
YoY :
-69.37%
-317.52
FCF Margin - %
FY2025Q1
YoY :
-29.22%
-2.08K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
583.1K
USD
2
3-6
Months
397.6K
USD
2
6-9
Months
456.3K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 869.7% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.8M
Volume
Months
6-9
1
189.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
583.1K
USD
2
3-6
Months
397.6K
USD
2
6-9
Months
456.3K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MGTX News & Events
Events Timeline
2025-08-14 (ET)
2025-08-14
08:02:54
MeiraGTx reports Q2 EPS (48c) vs (76c) last year
2025-08-09 (ET)
2025-08-09
13:28:34
Vinay Prasad returns to FDA as head of CBER
2025-05-13 (ET)
2025-05-13
08:06:48
MeiraGTx reports Q1 EPS (51c) vs. (32c) last year
Sign Up For More Events
Sign Up For More Events
News
5.0
07-23NASDAQ.COMInsider Sale: CFO & COO of $MGTX Sells 24,000 Shares
4.0
05-14BenzingaCoinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
4.0
05-14BenzingaChardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $35
Sign Up For More News
People Also Watch
FAQ
What is MeiraGTx Holdings PLC (MGTX) stock price today?
The current price of MGTX is 8.33 USD — it has decreased -0.12 % in the last trading day.
What is MeiraGTx Holdings PLC (MGTX)'s business?
What is the price predicton of MGTX Stock?
What is MeiraGTx Holdings PLC (MGTX)'s revenue for the last quarter?
What is MeiraGTx Holdings PLC (MGTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for MeiraGTx Holdings PLC (MGTX)'s fundamentals?
How many employees does MeiraGTx Holdings PLC (MGTX). have?